Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study

Sharma, Atul; Rath, Goura Kishor; Chaudhary, Surendra Pal; Thakar, Alok; Mohanti, Bidhu Kalyan; Bahadur, Sudhir

doi:10.1016/j.ejca.2011.06.010

Cited by 132 publications

(119 citation statements)

References 17 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…A total of 20 out to 21 studies indicated localization of an oncological disease: hematologic cancer [2], colon cancer [3], head and neck cancer [10,11], hematologic cancer [12,13,14], head and neck cancer [15,16,17,18,19,20], hematologic cancer [21], breast cancer [22], head and neck cancer [23,24,25,26,27], hematological cancer [28]. In all studies, the oncologic treatment method is described: chemotherapy [2], combined chemotherapy and radiotherapy [3,10,11], radiotherapy [11], chemotherapy [12,13,14], combined chemotherapy and radiotherapy [15,16], radiotherapy [17,18], combined chemotherapy and radiotherapy [18], chemotherapy [19], combined chemotherapy and radiotherapy [20], radiotherapy [20], chemotherapy [21], combined chemotherapy and radiotherapy [22,23], radiotherapy [24], combined chemotherapy and radiotherapy [25], radiotherapy [26], combined chemotherapy and radiotherapy [27], chemotherapy [28].…”

Section: Methodsmentioning

confidence: 99%

Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

et al. 2019

View full text Add to dashboard Cite

Background and objectives: Oral mucositis is one of the main adverse events of cancer treatment with chemotherapy or radiation therapy. It presents as erythema, atrophy or/and ulceration of oral mucosa. It occurs in almost all patients, who receive radiation therapy of the head and neck area and from 20% to 80% of patients who receive chemotherapy. There are few clinical trials in the literature proving any kind of treatment or prevention methods to be effective. Therefore, the aim of this study is to perform systematic review of literature and examine the most effective treatment and prevention methods for chemotherapy or/and radiotherapy induced oral mucositis. Materials and methods: Clinical human trials, published from 1 January 2007 to 31 December 2017 in English, were included in this systematic review of literature. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) protocol was followed while planning, providing objectives, selecting studies and analyzing data for this systematic review. “MEDLINE” and “PubMed Central” databases were used to search eligible clinical trials. Clinical trials researching medication, oral hygiene, cryotherapy or laser therapy efficiency in treatment or/and prevention of oral mucositis were included in this systematic review. Results: Results of the studies used in this systematic review of literature showed that laser therapy, cryotherapy, professional oral hygiene, antimicrobial agents, Royal jelly, L. brevis lozenges, Zync supplementation and Benzydamine are the best treatment or/and prevention methods for oral mucositis. Conclusions: Palifermin, Chlorhexidine, Smecta, Actovegin, Kangfuxin, L. brevis lozenges, Royal jelly, Zync supplement, Benzydamine, cryotherapy, laser therapy and professional oral hygiene may be used in oral mucositis treatment and prevention.

show abstract

Section: Methodsmentioning

confidence: 99%

Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A recent randomized clinical trial proposed the use of Lactobacillus brevis CD2 lozenges as a potential approach for the treatment of mucositis in patients with head and neck cancer undergoing chemotherapy or radiation therapy. L. brevis CD2 lozenges reduced the incidence of grade III and IV OM and were associated with a lower overall rate of mucositis as well as a higher rate of anticancer treatment completion in this population (Sharma et al 2012). A phase 1b study in patients with head and neck cancer receiving induction chemotherapy examined the use of an oral rinse (AG013) containing recombinant Lactococcus lactis, which was genetically engineered to secrete the mucosal protectant human trefoil factor 1 (a family of peptides that play important roles in the protection and repair of epithelial surfaces, including the gastrointestinal tract).…”

Section: Insights On Probiotics Host Communicationmentioning

confidence: 99%

Host-Microbiome Cross-talk in Oral Mucositis

Vasconcelos

Sanfilippo

Paster³

et al. 2016

J Dent Res

View full text Add to dashboard Cite

Oral mucositis (OM) is among the most common, painful, and debilitating toxicities of cancer regimen-related treatment, resulting in the formation of ulcers, which are susceptible to increased colonization of microorganisms. Novel discoveries in OM have focused on understanding the host-microbial interactions, because current pathways have shown that major virulence factors from microorganisms have the potential to contribute to the development of OM and may even prolong the existence of already established ulcerations, affecting tissue healing. Additional comprehensive and disciplined clinical investigation is needed to carefully characterize the relationship between the clinical trajectory of OM, the local levels of inflammatory changes (both clinical and molecular), and the ebb and flow of the oral microbiota. Answering such questions will increase our knowledge of the mechanisms engaged by the oral immune system in response to mucositis, facilitating their translation into novel therapeutic approaches. In doing so, directed clinical strategies can be developed that specifically target those times and tissues that are most susceptible to intervention.

show abstract

“…The immunosuppressed patients have earlier been mentioned as a group where probiotic bacteria should be avoided or used only with caution. However, a randomised, controlled trial with 200 patients found no serious adverse effects of the probiotic product (Sharma et al 2012 ). Furthermore, they found a statistically signifi cant reduction in the prevalence of mucositis (7 % vs. 28 %) and reduction of the proportion of patients with severe (grades III and IV) mucositis (52 % vs. 77 %).…”

Section: Oral Mucositismentioning

confidence: 97%

Use of Probiotics in Future Prevention and Treatment of Oral Infections

Jørgensen

Keller

2015

Oral Infections and General Health

View full text Add to dashboard Cite

The interest for probiotic bacteria to combat biofi lm-related diseases in the oral cavity has arisen during the last decade. The probiotic concept has successfully been used to control gastrointestinal diseases, such as antibiotic-associated diarrhoea and acute infectious diarrhoea. The potential mechanisms of action in the oral cavity are not fully understood, but there are thoughts to be a local effect in the mouth and systemic effect through immune regulation. The purpose of this chapter is to summarise our current knowledge of the potential for probiotics to improve oral and dental health and to discuss its potential in the future prevention of oral diseases. Despite some limitations, the currently available clinical studies appear expectant, and there seem to be evidence of probiotics to improve oral conditions such as dental caries, periodontitis and the colonisation of Candida . However, more long-term clinical studies are needed before evidence-based guidelines can be released.

show abstract

Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study

Cited by 132 publications

References 17 publications

Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

Host-Microbiome Cross-talk in Oral Mucositis

Use of Probiotics in Future Prevention and Treatment of Oral Infections

Contact Info

Product

Resources

About